terça-feira, 6 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 14, 2026

Where Will Alphabet Be in 5 Years?

View original at nasdaq.com
Where Will Alphabet Be in 5 Years? Today, the lowest-valued stock in the "Magnificent Seven" is Alphabet(NASDAQ: GOOG)(NASDAQ: GOOGL), and it's not close…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Google Search habits may be hard to kick due to being part of billions of people's daily routines

    80% confidence

  • By many metrics, I think we have the best model out there now

    80% confidence

  • The autonomous vehicle market size will be between $370 billion and $450 billion by 2033 according to various research firms

    80% confidence

  • Google's free ad-based Search franchise may give it a competitive advantage over AI startups that rely on subscriptions

    80% confidence

  • In five years, Alphabet's earnings will be more balanced between Search, YouTube, Google Cloud, and Waymo

    80% confidence

  • Alphabet is the lowest-valued stock in the Magnificent Seven and trades at a lower valuation than the overall market

    80% confidence

  • Alphabet stock is not one of the 10 best stocks to buy right now

    80% confidence

  • Waymo was already providing 200,000 paid rides per week as of early 2025

    80% confidence

  • AI overviews are monetized at the same rate as traditional Search

    80% confidence

  • Gemini 2.5 compares favorably to ChatGPT 4.5 in several use cases according to positive reviews

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Where Will Alphabet Be in 5 Years? — Source | Via News | pt.VIA.NEWS